Author + information
- Received December 31, 1993
- Revision received June 8, 1994
- Accepted June 13, 1994
- Published online November 15, 1994.
- Jonathan S. Reiner, MDh,∗,
- Conor F. Lundergan, MDh,
- Marcel Van Den Brand, MDa,
- Jean Boland, MDb,
- Mark A. Thompson, MD, FACCh,
- Jacques Machecourt, MDc,
- PY Antoinne, MDd,
- George S. Pilcher, MDe,
- Cynthia A. Fink, BSh,
- Jeffrey R. Burton, MD, FACCf,
- Maarten L. Simoons, MD, FACCa,
- Robert M. Califf, MD, FACC#,
- Eric J. Topol, MD, FACCg,
- Allan M. Ross, MD, FACCh,
- For the GUSTO Angiographic Investigators
- ↵∗Address for correspondence: Dr. Jonathan S. Reiner, Division of Cardiology, George Washington University, 2150 Pennsylvania Avenue, NW, Washington, D.C. 20037.
Objectives. The purpose of this study was to determine whether early qualitative or quantitative angiographic features can predict reocclusion after initially successful coronary thrombolysis.
Background. Although both the benefits of early reperfusion and the consequences of subsequent reocclusion after thrombolysis for acute myocardial infarction have been well described, efforts to describe angiographic markers of lesions at high risk for reocclusion have produced conflicting results. The Global Utilization of Streplokinase and t-PA for Occluded Coronary Arteries (GUSTO) angiographic trial provides the opportunity to examine these relations in the largest single, prospective patient cohort studied to date.
Methods. We studied 559 patients undergoing follow-up angiography at 90 min and 5 to 7 days after thrombolysis in the GUSTO trial. Patients received one of four thrombolytic regimens: 1) streptokinase with intravenous heparin; 2) streptokinase with subcutaneous heparin; 3) accelerated-dose recombinant tissuetype plasminogen activator (rt-PA) with intravenous heparin; or 4) a combination of streptokinase and conventionally dosed rt-PA with intravenous heparin. Qualitative variables examined at 90-min angiography included Thrombolysis in Myocardial Infarction (TIMI) flow grade, visible thrombus and lesion morphology. Quantitative variables included percent diameter stenosis, percent area stenosis minimal lumen diameter and lesion length. The study contained a power > 0.85 to detect clinically important differences in percent diameter stenosis, percent area stenosis and minimal lumen diameter between the groups with subsequent reocclusion and sustained patency at the p = 0.05 level.
Results. At follow-up, 33 patients (5.9%) had reocclusion. The reocclusion rate for patients with early TIMI grade 2 flow was 6.3% versus 5.6% for TIMI grade 3 flow (p = NS). When the group with reocclusion was compared with the group with continued patency, there were no differences in presence of early visible thrombus, complex lesion morphology, percent diameter stenosis, percent area stenosis, minimal lumen diameter or lesion length.
Conclusions. Our findings demonstrate that neither qualitative nor quantitative angiographic variables at 90 min after initiation of thrombolytic therapy can be used to predict subsequent coronary reocclusion.
☆ This study was funded by a combined grant from Bayer, New York, New York: CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceutical, Wilmington. Delaware; and Sanofi Pharmaceutical, Paris, France.
- Received December 31, 1993.
- Revision received June 8, 1994.
- Accepted June 13, 1994.